New biological insights into progressive multiple sclerosis
A new study identified new protein targets and drug candidates, including opportunities to repurpose existing drugs. Six key proteins were highlighted as potentially providing new insights and supporting future treatment development for progressive multiple sclerosis (MS).
“Using a multi-omics approach, we prioritized 48 genetically supported proteins, identified 14 proteins with therapeutic potential, and highlighted 13 non-MS drugs with potential for repurposing,” says Yuan Jiang, affiliated with the Department of Medicine, Huddinge, and the Department of Clinical Neuroscience in Solna, and the lead author of the study. “Through further validation, we identified six key proteins that may provide new biological insight into progressive multiple sclerosis and support future therapeutic exploration.”
These findings, published in Journal of Neuroinflammation, may be of interest to professionals in neurology, neuroimmunology, genetics, drug development, and precision medicine, especially given the urgent need for better treatments targeting disease progression and neurodegeneration in multiple sclerosis.
The study provides information on funding and any reported conflicts of interest.
Publication
“Multi-omics integration provides biological insight and prioritizes potential drug targets in multiple sclerosis progression”, Yuan Jiang, Jinyu Xiao, Ingrid Kockum, Pernilla Stridh, Qianwen Liu, Tomas Olsson, Lars Alfredsson & Xia Jiang. Journal of Neuroinflammation, online 2 June 2026, doi: org/10.1186/s12974-026-03895-z.